Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEBT-908 in Relapsed/Refractory Hematologic Malignancies
NCT06082596Phase 1Completed
- Sponsor
- BeBetter Med
- Start
- Mar 2016
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ifupinostat in non-Hodgkin lymphoma (NHL), Hodgkin lymphoma (HL), multiple myeloma (MM) and 1 more, sponsored by BeBetter Med. Primary endpoints: Dose-Limiting Toxicity at 21 days and Maximum Tolerated Dose at 21 days. Started Mar 2016; status: completed.
02
Drugs
ifupinostat
03
Conditions
non-Hodgkin lymphoma (NHL)Hodgkin lymphoma (HL)multiple myeloma (MM)chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT06082596.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06082596.